Sarah Tabrizi

Quick Facts

Full Name	Sarah Tabrizi
Occupation	Researcher
Date Of Birth	Sep 26, 1965(1965-09-26)
Age	59
Birthplace	London
Country	United Kingdom
Horoscope	Virgo

Sarah Tabrizi Biography

Sarah Tabrizi is one of the most popular and richest Researcher who was born on September 26, 1965 in London, United Kingdom. Sarah Joanna Tabrizi FMedSci (born 26 September 1965) is a British-Iranian neuroologist and neuroscientist working in Neurodegeneration research, specifically Huntington’s disease. She is an Associate Professor and Joint Director of the Department of Neurodegenerative Diseases at the UCL Institute of Neurology; Director and founder of the UCL Huntington’s Disease Centre; an Investigator in Chief of UCL’s UK Dementia Research Institute at UCL as well as an honorary consultant Neurologist in the National Hospital for Neurology and Neurosurgery, Queen Square, London in which she established the Multidisciplinary Huntington’s Disease Clinic. Its UCL Huntington’s Disease Centre opened its doors officially inaugurated on March 1, 2017 by UCL Provost and President Michael Arthur.

As of November, Tabrizi had authored over 300 articles, and more than 22,000 citations for her work.

In 2017, Tabrizi was the topic of a profile piece that appeared in The Lancet Neurology.

Sarah Tabrizi Net Worth

Sarah Tabrizi is one of the richest Researcher from United Kingdom. According to our analysis, Wikipedia, Forbes & Business Insider, Sarah Tabrizi 's net worth $5 Million. (Last Update: December 11, 2023)

Tabrizi received a first-class degree in biochemistry at Heriot-Watt University in 1986 and an MBChB from The University of Edinburgh in 1992 and was awarded the Gold Medal (Ettles Scholar) for the most prestigious medical student. She earned the PhD in the department of neurology at University College London in 2000. While she was an intern neurologist at the National Hospital for Neurology and Neurosurgery (NHNN), Queen Square, Sarah worked for Professors Anita Harding and David Marsden who left a lasting impression on her. She completed the MRC Clinical Training Fellowship PhD researching the role of mitochondrial dysfunction during neurodegeneration along with Tony Schapira and Gillian Bates between 1996 and 1999. She then received an Department of Health National Clinician Scientist fellowship in UCL Institute of Neurology. UCL Institute of Neurology in 2002 to work alongside John Collinge and Charles Weissmann. Her position was elevated to UCL Professor and Clinical Senior Lecturer in the year 2003. She was promoted to Honorary Consultant in. She was promoted becoming a Reader in 2007,, and then Full Professor in 2009.

Tabrizi delivered a keynote speech during the 2015 Google Zeitgeist Minds conference about the trial and the potential of gene silencing in neurodegenerative diseases. Tabrizi was the principal Clinical Investigator in the initial clinical trial for a ‘gene silencing’ or huntingtin-lowering medication for patients suffering from Huntington’s disease. In the announcement of “top top of the line’ results from the safety trial in Phase 1b/2a in December 2017 garnered widespread worldwide and national press coverage, and was featured in articles in BBC News, Guardian and Nature. In May 2019, the complete outcomes were announced by The New England Journal of Medicine.

Tabrizi is distinguished for her work on mechanisms of cellular neurodegeneration and in particular Huntington’s disease pathobiology, biomarkers, outcome measures and clinical trials. Amongst her achievements, she has identified a key role for the innate immune system in the pathogenesis of Huntington’s disease, published the first assay of the mutant HD protein in human blood cells, and designed and led two major, international, influential research initiatives, TRACK-HD and Track-On HD. To date these studies have yielded fundamental new insights into the preclinical phase of neurodegeneration in Huntington’s disease including identifying predictors of disease onset, progression, evidence of brain compensation and plasticity and neurobiological changes occurring twenty years before predicted disease onset, and her work established a battery of clinical trial outcome measures. Recently her work identified an important new genetic modifier of disease progression in Huntington’s disease, which has opened up new avenues of research into targeting DNA repair pathways as possible therapeutics for Huntington’s disease.

Height, Weight & Body Measurements

Sarah Tabrizi height Not available right now. Sarah weight Not Known & body measurements will update soon.

Who is Sarah Tabrizi Dating?

According to our records, Sarah Tabrizi is possibily single & has not been previously engaged. As of December 1, 2023, Sarah Tabrizi’s is not dating anyone.

Relationships Record : We have no records of past relationships for Sarah Tabrizi. You may help us to build the dating records for Sarah Tabrizi!

Facts & Trivia

Sarah Ranked on the list of most popular Researcher. Also ranked in the elit list of famous people born in United Kingdom. Sarah Tabrizi celebrates birthday on September 26 of every year.